Cliff Bechtold

Cliff is a 27-year veteran of the Pharmaceutical industry with a broad drug development experience and a track record of optimizing organizations and capabilities. Prior to joining Biohaven, Cliff was the Development Lead for Genetically Defined Diseases at Bristol-Myers Squibb Company (BMS). In this role he led the teams which developed innovative strategies and executed on two novel programs in neuromuscular and neurodegenerative diseases. In addition to these disease areas, Cliff has in-depth experience in all stages of program advancement from discovery to launch in diverse disease areas including virology, oncology, immunology, cardiovascular and neuroscience. This includes key leadership roles for the development and launch of Reyataz® and Sprycel®. At BMS, he also served as Head of Biologics Strategy and Operations with a key role in optimizing the company’s biologics development and manufacturing capabilities. As the Head of Strategic Operations at Adnexus Therapeutics, Cliff oversaw the organizational optimization and strategic integration. Through his career, Cliff has held multiple positions in Discovery, Clinical Development and leadership roles in Project Planning and Management. Cliff is currently serving as a member of the TREAT-NMD Advisory Committee for Therapeutics (TACT), ImagingDMD scientific advisory board and consults for Project Parent Muscular Dystrophy (PPMD). Cliff holds a Master of Science degree in Medical Microbiology from Creighton University School of Medicine and a Bachelor of Science degree from South Dakota State University.